IFCC COVID-19患者生化与血液学监测临时指南
国际临床化学与检验医学联合会(IFCC)COVID-19工作组发布临时指南,针对确诊COVID-19的儿童和成人患者,就生化与血液学检测的临床指征、项目选择与解读、注意事项及当前局限性给出循证建议,以指导全球临床实验室在大流行应对中发挥检验作用。
要点
- 生化与血液学检测有助于COVID-19患者分层和预后判断,与机械通气、重症监护、多器官衰竭或死亡等不良结局相关。
- 指南涵盖检测临床指征、项目选择与解读、解读注意事项及当前局限性四方面内容。
- 多数临床实验室已常规开展这些检测,但其在COVID-19管理中的临床价值尤其儿科领域仍存争议。
核心结论
- IFCC COVID-19工作组基于证据发布临时指南,强调生化与血液学检测对COVID-19患者分层和预后判断的贡献。
研究设计与样本
- IFCC COVID-19工作组制定的临时指南,针对确诊COVID-19的儿童和成人患者。
主要发现
- 常规生化与血液学检测与COVID-19患者需机械通气、需重症监护、进展为多系统器官衰竭和/或死亡等不良结局相关。
- 这些检测在COVID-19管理中的临床价值尤其在儿科领域仍存争议,复合临床风险评分在COVID-19预后判断中的价值亦有争议。
关键数值与推荐
- 指南就检测临床指征、检测项目选择与解读建议、解读注意事项及当前局限性四方面提供临时指导。
临床怎么用
- 指南为全球临床实验室提供实践指导,强调生化与血液学检测在集体大流行应对中的贡献。
局限性
- 指南指出当前生化与血液学监测COVID-19患者存在局限性,具体内容见原文相关部分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Routine biochemical and hematological tests have been reported to be useful in the stratification and prognostication of pediatric and adult patients with diagnosed coronavirus disease (COVID-19), correlating with poor outcomes such as the need for mechanical ventilation or intensive care, progression to multisystem organ failure, and/or death. While these tests are already well established in most clinical laboratories, there is still debate regarding their clinical value in the management of COVID-19, particularly in pediatrics, as well as the value of composite clinical risk scores in COVID-19 prognostication. This document by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications for testing, (B) recommendations for test selection and interpretation, (C) considerations in test interpretation, and (D) current limitations of biochemical/hematological monitoring of COVID-19 patients. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide, underscoring the contribution of biochemical and hematological testing to our collective pandemic response.
引用
- Thompson S, Bohn MK, Mancini N, et al. IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients. Clin Chem Lab Med. 2020. PMID: 33027044. doi:10.1515/cclm-2020-1414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。